Key result
Non-ischemic dilated cardiomyopathy was associated with higher in-hospital mortality (10.4% vs 9.6%, aOR 1.08) compared to ischemic cardiomyopathy in patients hospitalized for ventricular tachycardia.
Why the study?
Ventricular tachycardia causes substantial morbidity and mortality in structural heart disease, but real-world comparisons between ischemic cardiomyopathy and non-ischemic dilated cardiomyopathy remain limited.
Does underlying non-ischemic dilated cardiomyopathy versus ischemic cardiomyopathy affect in-hospital mortality and outcomes in patients admitted with ventricular tachycardia?
Cohort (n=622,092)
Yes
Does underlying non-ischemic dilated cardiomyopathy versus ischemic cardiomyopathy affect in-hospital mortality and outcomes in patients admitted with ventricular tachycardia?
Odds Ratio: 1.08 (95% CI 1.02–1.13)
Absolute Event Rate: 10.4% vs 9.6%
p-value: p=<0.001
Patients hospitalized for ventricular tachycardia with underlying non-ischemic dilated cardiomyopathy have higher in-hospital mortality and readmission rates compared to those with ischemic cardiomyopathy, highlighting the need for etiology-specific management strategies.
Background Ventricular tachycardia (VT) is a major cause of morbidity and mortality in patients with structural heart disease, yet real‐world comparisons between ischemic cardiomyopathy (ICM) and non‐ischemic dilated cardiomyopathy (NIDCM) remain limited. Methods The national readmission database (2016–2020) was used to identify hospitalizations for VT. Cohorts were stratified based on underlying cardiomyopathy. A Propensity Score Matching (PSM) model matched ICM to NIDCM patients. Pearson's x2 test was applied to PSM‐matched cohorts to compare outcomes. Results We identified 622,092 VT hospitalizations, of which 575,312 (92.4%) had ICM and 46,780 (7.5%) had NIDCM. Outcomes were compared using multivariable logistic regression and propensity score matching (25,919 matched pairs). Despite being younger, NIDCM patients had higher in‐hospital mortality (10.4% vs. 9.6%, p < 0.001; aOR 1.08), stroke (1.7% vs. 1.2%, aOR1.42), acute heart failure (65% vs. 59%, aOR 1.36), acute kidney injury (46.1% vs. 41.7%, aOR1.35), endotracheal intubation (13.1% vs. 14.5%, aOR 1.06), ICD implantation (3.9% vs. 3.5%, aOR1.23), and VT ablation (1.0% vs. 0.5%, aOR1.76). Readmission rates were significantly higher in NIDCM at 30 days (10.4% vs. 8.7%, p = 0.019), 90 days (22.7% vs. 20.0%, p = 0.483), and 180 days (30.7% vs. 27.3%, p = 0.001). In contrast, ICM patients had higher rates of sudden cardiac arrest (10.6% vs. 5.9%, aOR0.55), major adverse cardiovascular events (78.9% vs. 52.2%, aOR0.24), cardiogenic shock (18.4% vs. 12.1%, aOR0.59), ECMO (0.9% vs. 0.4%, aOR0.48), and LVAD use (0.5% vs. 0.3%, aOR0.58). Mortality declined over time in ICM (8.5% in 2016 to 8.2% in 2020, p ‐trend = 0.006), but not in NIDCM. Conclusion These findings highlight distinct clinical profiles and emphasize the need for targeted management strategies for VT based on the cardiomyopathy subtype.
No takes yet. Share an insight, caveat, or question.
Chowdhury et al. (2026) conducted a cohort in Ventricular tachycardia in structural heart disease (n=622,092). Non-ischemic dilated cardiomyopathy (NIDCM) vs. Ischemic cardiomyopathy (ICM) was evaluated on In-hospital mortality (aOR 1.08, 95% CI 1.02-1.13, p=<0.001). Non-ischemic dilated cardiomyopathy was associated with higher in-hospital mortality (10.4% vs 9.6%, aOR 1.08) compared to ischemic cardiomyopathy in patients hospitalized for ventricular tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: